Abstract
Since cholecystokinin (CCK) was discovered in 1928 (Ivy and Oldberg 1928) numerous stud.~es have sought to determine its physiological function in animals and in humans. These investigations have been complicated by the subsequent discovery of different types of CCK receptors, subclassified as the peripheral ( ty~ A) and central (type B) CCK receptors (Moran et al. 1986; Dourish and Hill 1987). Although located primarily in the digestive system, peripheral-type receptors are also found in the centrai aervous system, in ,~ species-specific distfibution (Mor~n et ~1. 1986; Hill et al. 1987). The recent development of CCK receptor antagonists ~eieetive for the peripheral-type receptor, e.g., MK-329 (previously named L364,718 [3S(-)-N-(2,3-dihydro-l-methyl-2oxo-5-phenyi-l-H-i, 4~b~,nzodiazepine-3-YL)1H ind01e-2-carbox~oe_o (Evans et al. 1986;
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.